Across TCGA pan-cancer cohorts, OR51I2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR51I2 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OR51I2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR51I2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, COAD, and BLCA are the cancer types where OR51I2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.625	.011	30	view →
COAD	OS	Median	All	0.159	0.799	.002	21	view →
BLCA	DFS	Median	All	0.096	0.626	<.001	12	view →
LUAD	OS	Median	All	0.435	0.688	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OR51I2 tumor-vs-normal RNA expression · all OR51I2 data types